Related Experiment Video
Updated: May 4, 2026

A Fluorescence-based Protocol for Preliminary Screening of Protein Synthesis Inhibitors from Natural Sources
Published on: January 27, 2026
Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1
Ying Wang1, David M Lonard1, Yang Yu1
1Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
Abstract:
Virtually all transcription factors partner with coactivators that recruit chromatin remodeling factors and interact with the basal transcription machinery. Coactivators have been implicated in cancer cell proliferation, invasion, and metastasis, including the p160 steroid receptor coactivator (SRC) family composed of SRC-1 (NCOA1), SRC-2 (TIF2/GRIP1/NCOA2), and SRC-3 (AIB1/ACTR/NCOA3). Given their broad involvement in many cancers, they represent candidate molecular targets for new chemotherapeutics. Here, we report on the results of a high-throughput screening effort that identified the cardiac glycoside bufalin as a potent small-molecule inhibitor for SRC-3 and SRC-1. Bufalin strongly promoted SRC-3 protein degradation and was able to block cancer cell growth at nanomolar concentrations. When incorporated into a nanoparticle delivery system, bufalin was able to reduce tumor growth in a mouse xenograft model of breast cancer. Our work identifies bufalin as a potentially broad-spectrum small-molecule inhibitor for cancer.
Insights
Bufalin, a cardiac glycoside, effectively inhibits SRC-3 and SRC-1 coactivators, crucial in cancer progression. This small molecule shows promise as a broad-spectrum cancer therapeutic, reducing tumor growth in preclinical models.
Area of Science:
- Molecular Biology
- Oncology
- Pharmacology
Background:
- Transcription factors rely on coactivators to regulate gene expression.
- The p160 steroid receptor coactivator (SRC) family (SRC-1, SRC-2, SRC-3) plays a significant role in cancer cell proliferation, invasion, and metastasis.
- SRC family members are potential therapeutic targets for novel chemotherapeutics.
Purpose of the Study:
- To identify small-molecule inhibitors targeting the SRC coactivator family.
- To evaluate the efficacy of identified inhibitors in preclinical cancer models.
Main Methods:
- High-throughput screening of small molecules.
- Assays to determine SRC-3 and SRC-1 inhibition.
- In vitro cancer cell growth inhibition assays.
- In vivo mouse xenograft models of breast cancer using nanoparticle delivery systems.
Main Results:
- Bufalin was identified as a potent inhibitor of SRC-3 and SRC-1.
- Bufalin induced SRC-3 protein degradation.
- Bufalin demonstrated potent cancer cell growth inhibition at nanomolar concentrations.
- Nanoparticle-formulated bufalin reduced tumor growth in a mouse xenograft model.
Conclusions:
- Bufalin is a potent small-molecule inhibitor of SRC-3 and SRC-1.
- Bufalin exhibits anti-cancer activity both in vitro and in vivo.
- Bufalin represents a promising candidate for a broad-spectrum cancer therapeutic.
Related Concept Videos
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Co-activators and Co-repressors
Inhibitors of Bacterial Protein Synthesis
Drugs that Destabilize Microtubules
Antifungal Agents
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...

